Cancer stem cell markers in breast cancer: Pathological, clinical and prognostic significance

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Ali, H Raza ^a,b   Dawson, Sarah Jane ^a,b,c   Blows, Fiona M ^d   Provenzano, Elena ^b,c   Pharoah, Paul D ^a,b,d   Caldas, Carlos ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA6 INTEGRIN; CD24 ANTIGEN; CD44V ANTIGEN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STEM CELL; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST; BREAST TUMOR; CANCER STAGING; CLUSTER ANALYSIS; COHORT ANALYSIS; GENE EXPRESSION PROFILING; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL;

AGED; BREAST; BREAST NEOPLASMS; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 81555231202     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3061     Document Type: Article

References (38)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
2. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73. 10.1016/j.cell.2009.12.007, 20074520.
3. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. 10.1038/35102167, 11689955.
5. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29:32-45. 10.1002/stem.563, 21280157.
6. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
7. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham AD. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008, 122:298-304. 10.1002/ijc.23103, 17935134.
8. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432. 10.1016/j.stem.2010.02.018, 2884275, 20452317.
9. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ, Lee WH. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 2009, 4:e8377. 10.1371/journal.pone.0008377, 2793431, 20027313.
10. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci USA 2003, 100(Suppl 1):11842-11849. 304096, 14504387.
11. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007, 7:791-799. 10.1038/nrc2212, 17851544.
12. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:R53. 10.1186/bcr2108, 2481503, 18559090.
13. Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008, 39:1096-1102. 10.1016/j.humpath.2007.12.003, 18495204.
14. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010, 16:876-887. 10.1158/1078-0432.CCR-09-1532, 2818503, 20103682.
15. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 2011, 28:745-752. 10.1007/s12032-010-9530-3, 20405247.
16. Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010, 123:97-108. 10.1007/s10549-009-0619-3, 19911270.
17. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010, 176:2131-2138. 10.2353/ajpath.2010.090712, 2861079, 20228222.
18. Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL, Luben R, Wareham NJ, Easton DF, Dunning AM, Ponder BA. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 2005, 14:2349-2356. 10.1093/hmg/ddi237, 16000320.
19. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M, Sauter G, Kallioniemi O. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
20. Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J, Cheang M, Gelmon K, Nielsen T, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med 2010, 7:e1000279. 10.1371/journal.pmed.1000279, 2876119, 20520800.
21. Pharoah PD, Caldas C. Genetics: How to validate a breast cancer prognostic signature. Nat Rev Clin Oncol 2010, 7:615-616. 10.1038/nrclinonc.2010.142, 20981123.
22. Azzato E, Greenberg D, Shah M, Blows F, Driver K, Caporaso N, Pharoah P. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?. Br J Cancer 2009, 100:1806-1811. 10.1038/sj.bjc.6605062, 2695697, 19401693.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, . Diagnostics SSotN-EWGoC Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184. 10.1093/jnci/dji237, 16106022, Diagnostics SSotN-EWGoC.
24. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
25. Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, van de Rijn M. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002, 161:1557-1565. 10.1016/S0002-9440(10)64434-3, 1850765, 12414504.
26. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002, 12:1-6. 10.1016/S1047-2797(01)00250-2, 11750233.
27. Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD. Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 2011, 104:693-699. 10.1038/sj.bjc.6606078, 21266980.
28. Royston P. Multiple imputation of missing values. Stata J 2004, 4:227-241.
29. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata J 2009, 9:466-477.
30. Moons KG, Donders RA, Stijnen T, Harrell FE. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 2006, 59:1092-1101. 10.1016/j.jclinepi.2006.01.009, 16980150.
31. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
32. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785. 10.1093/jnci/djj495, 17179479.
33. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010, 102:1637-1652. 10.1093/jnci/djq361, 2970576, 20935265.
34. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
35. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273. 10.1016/j.ccr.2007.01.013, 17349583.
36. Liu R, Wang X, Chen G, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke M. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356:217-226. 10.1056/NEJMoa063994, 17229949.
37. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15:4234-4241. 10.1158/1078-0432.CCR-08-1479, 19509181.
38. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe HJ, Imhof BA. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995, 55:901-906.